We don’t follow footsteps.
We create the path.

News & events

Updated Hemophilia B Data Presented Spark Therapeutics presented data from its Phase 1/2 study of investigational SPK-9001 at the World Federation of Hemophilia 2018 Congress  

Read More read more

World’s Most Innovative Companies Spark Therapeutics named one of the Top 10 Most Innovative Companies in Biotech by Fast Company

Read More read more

Gene Therapy Approval FDA has approved our gene therapy product

Read More read more

New Posting on Health Affairs Magazine Blog: Advancing Gene Therapies Through Value-Based Payment Reform

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.
Learn More